SEC Form 4 · accession 0001144204-17-004109
INTERLEUKIN GENETICS INC · ILIU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth S Kornman
Officer — President and CSO · Director
Period of report
Jan 25, 2017
Accepted (ET)
Jan 26, 2017 · 6:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001037649
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $0.1237 | Jan 25, 2017 | A | 3,625,746 | A | — | Jan 25, 2027 | Common Stock | 3,625,746 | 3,625,746 | D |
Explanation of responses
- F1The exercise price of the option is the closing price of the Issuer's common stock on the OTCQB on January 25, 2017, which was the grant date of the option.
- F2The option vests as to 25% of the shares on January 25, 2018, and 1/36th of the shares on the first day of each month beginning on February 1, 2018.